History of development of anti-RANKL antibody

DOI

Bibliographic Information

Other Title
  • 抗RANKL抗体の開発の経緯

Search this article

Abstract

<p>　In the development of the world's first anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody, denosumab, studies conducted by Japanese researchers have made a great contribution. The first achievement is the establishment of a system for co-culture system of osteoblasts and bone marrow macrophages, which contributed to the verification of the hypothesis that osteoblasts determine the fate of osteoclasts; the second is the discovery of osteoclastogenesis inhibitory factor (OCIF/OPG); and the third is the identification of osteoclast differentiation factor or RANKL, which is a target protein of OCIF. This identification of RANKL prompted drug discovery, leading to the development of denosumab by Amgen USA Inc. In 2010, denosumab was approved as a therapeutic agent for osteoporosis in the EU and the USA, and in 2017, a new indication "Inhibition of progression of bone erosion associated with rheumatoid arthritis" was approved in Japan, ahead of other countries in the world. In the realization of the new indication, Japanese clinicians on rheumatoid arthritis have also made a remarkable contribution. In this article, we present the developmental history of denosumab following the identification of RANKL, from its basic research to clinical application.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top